Who has been buying S Biomedics stock?

0 distinct insiders have filed 0 disclosed insider purchases in S Biomedics (304360), most recently on 2025-09-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does S Biomedics have?

S Biomedics has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-03-25 to 2025-09-29.

Where does StockDrifts get S Biomedics insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

S Biomedics 304360

Company

에스바이오메딕스S Biomedics

Insiders

Buys

Total Value

—

Avg Return

—

Last Filing

2025-09-29

S Biomedics (304360) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for S Biomedics is dated 2024-03-25; the most recent is 2025-09-29. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2025-09-29	BUY	주식매수청구권 행사	김상헌 Kim Sang-heon	Other non-executive directors	15.0K	₩25,600	+48.0%	₩384M ($267K)
2025-09-29	SELL	기타	조명수 Jo Myung Soo	Managing Director	-50.0K	₩25,600	-48.0%	₩1.3B ($889K)
2025-09-29	SELL	기타	김상헌 Kim Sang-heon	Other non-executive directors	-15.0K	₩25,600	-48.0%	₩384M ($267K)
2025-09-29	BUY	주식매수청구권 행사	조명수 Jo Myung Soo	Managing Director	50.0K	₩25,600	+48.0%	₩1.3B ($889K)
2025-03-24	BUY	PROGRAM	홍기동 Hong Ki-dong	moving	5.0K	₩29,200	+29.8%	₩146M ($101K)
2025-03-19	BUY	PROGRAM	나현섭 Na Hyun-seop	Managing Director	5.5K	₩26,000	+45.8%	₩143M ($99K)
2025-03-19	BUY	PROGRAM	김은희 Eunhee Kim	Managing Director	10.0K	₩26,000	+45.8%	₩260M ($181K)
2025-03-19	BUY	PROGRAM	정세균 Jeong Sye-kyun	moving	5.0K	₩26,000	+45.8%	₩130M ($90K)
2025-03-19	BUY	PROGRAM	김동욱 Kim Dong-wook	CEO	28.0K	₩26,000	+45.8%	₩728M ($506K)
2025-03-19	BUY	PROGRAM	김동욱 Kim Dong-wook	CEO	40.0K	₩26,000	+45.8%	₩1.0B ($722K)
2025-03-19	BUY	PROGRAM	조명수 Jo Myung Soo	Managing Director	3.0K	₩26,000	+45.8%	₩78M ($54K)
2024-06-11	BUY	주식매수청구권 행사	조명수 Jo Myung Soo	Managing Director	4.0K	₩48,850	-22.4%	₩195M ($136K)
2024-06-11	BUY	주식매수청구권 행사	김상헌 Kim Sang-heon	Other non-executive directors	5.0K	₩48,850	-22.4%	₩244M ($170K)
2024-06-11	BUY	기타	김상헌 Kim Sang-heon	Other non-executive directors	15.0K	₩48,850	-22.4%	₩733M ($509K)
2024-06-11	BUY	주식매수청구권 행사	나현섭 Na Hyun-seop	Managing Director	2.5K	₩48,850	-22.4%	₩122M ($85K)
2024-06-11	BUY	기타	나현섭 Na Hyun-seop	Managing Director	7.5K	₩48,850	-22.4%	₩366M ($254K)
2024-06-11	BUY	기타	KANG SAEIL	CEO	12.0K	₩48,850	-22.4%	₩586M ($407K)
2024-06-11	BUY	기타	조명수 Jo Myung Soo	Managing Director	53.0K	₩48,850	-22.4%	₩2.6B ($1.8M)
2024-06-11	BUY	주식매수청구권 행사	조명수 Jo Myung Soo	Managing Director	1.0K	₩48,850	-22.4%	₩49M ($34K)
2024-03-25	BUY	PROGRAM	김동욱 Kim Dong-wook	CEO	20.0K	₩10,190	+271.9%	₩204M ($142K)

Frequently asked questions

Who has been buying S Biomedics stock?: 0 distinct insiders have filed 0 disclosed insider purchases in S Biomedics (304360), most recently on 2025-09-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does S Biomedics have?: S Biomedics has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-03-25 to 2025-09-29.
Where does StockDrifts get S Biomedics insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for S Biomedics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.